Results: 150 pts were randomized: median age was 59 years (21-86), 56% male, ECOG PS 0 (57%)/1 (43%), prior chemotherapy 24%. Median number of 28-day treatment cycles were 13 (E+B) and 12 (E); range 1-44. Median follow up was 25.9 months. Pts on E+B experienced more grade 3 AEs, including diarrhea (14% vs. 3%; p = 0.01), hyponatremia (12% vs. 3%; p = 0.02), hypophosphatemia (11% vs. 3%; p=0.04), proteinuria (16% vs. 1%; p = 0.001), and hypertension (41% vs. 12%; p < 0.0001). The frequency of grade 4 AEs was 11% in both arms. Median PFS was 16.7 mos (E+B) vs. 14 mos (E); HR=0.80 (95% CI: 0.55, 1.17; 116 PFS events), 1-sided p= 0.12. Median OS was 36.7 mos (E+B) vs. 35.0 mos (E), HR =0.75 (95% CI: 0.42-1.33; 49 OS events), 1-sided p=0.16. E+B was associated with a significantly higher RR (31%) compared to E alone (12%), p=0.005).
Conclusions:
Treatment with E+B led to superior PFS compared to E but with more adverse events in this randomized phase II study. The RR was significantly higher in pts treated with E+B. The combination of E+B warrants further investigation in pts with advanced pNET.
